X
XENE icon

Xponance’s Xenon Pharmaceuticals XENE Stock Holding History

Xponance’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$492K Buy
8,465
+2,490
+42% +$115K ﹤0.01% 1024
2025
Q4 		$268K Buy
5,975
+8
+0.1% +$336 ﹤0.01% 1238
2025
Q3 		$240K Buy
+5,967
New +$210K ﹤0.01% 1269

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Xponance's XENE Position: Q1 2026 in Review

Xponance increased its Xenon Pharmaceuticals (XENE) stake by 42% in Q1 2026, buying an estimated $115K and bringing the position to 8,465 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Xponance first reported a position in XENE in Q3 2025 and has held it in 3 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Xponance held 8,465 shares of Xenon Pharmaceuticals worth $492K as of Q1 2026.
  • Xponance bought 2,490 Xenon Pharmaceuticals shares in Q1 2026, an estimated $115K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1024 holding.
  • Xponance first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.